STZ - Constellation Brands, Inc.

NYSE - NYSE Delayed Price. Currency in USD
-3.21 (-1.76%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close182.86
Bid176.82 x 800
Ask179.59 x 800
Day's Range179.45 - 183.40
52 Week Range150.37 - 214.48
Avg. Volume1,072,855
Market Cap34.453B
Beta (3Y Monthly)0.67
PE Ratio (TTM)44.99
EPS (TTM)3.99
Earnings DateJan 7, 2020 - Jan 13, 2020
Forward Dividend & Yield3.00 (1.63%)
Ex-Dividend Date2019-11-07
1y Target Est226.90
  • ‘Cannabis 2.0’ May Not Be Enough to Save Canopy Growth Stock

    ‘Cannabis 2.0’ May Not Be Enough to Save Canopy Growth Stock

    It's been a rough 2019 for Canopy Growth (NYSE:CGC) stock. But the launch of the company's "Cannabis 2.0" products next month could change that. Canopy and the pot space at-large could rebound if sales of beverages, edibles, and vapes live up to expectations.Source: Jarretera / But is this enough to move the needle for Canopy Growth stock? Even after a nearly 65% decline from its 52-week high, shares trade at a high valuation. Strategic partner Constellation Brands' (NYSE:STZ) multi-billion dollar investment provided a cash cushion. However, as the company burns through cash, Canopy could eventually need additional capital infusions.The pot space is betting big on "Cannabis 2.0". Does this mean its time to buy ahead of launch? Don't bet the ranch. While the shellacked share prices of pot stocks could rebound, all bets are off regarding upside.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut before we get to what will be, let's review what was. No Escaping a Terrible QuarterShares of Canopy Growth dropped to a two-year low yesterday after the company reported a weaker-than-expected $374.6 million net loss in its fiscal second quarter. It seems consumers lost interest in cannabis in the period, leading CGC to report $47.9 million in charges, including a $15.9 million inventory write-down.To be sure, net revenue in the quarter tripled YoY to $76.6 million, compared with $23.3 million in the same quarter last year, but it was off from Q1's $90.5 million.What happened? Acting CEO Mark Zekulin blamed Ontario's slow intro of pot retail stores as the biggest contributor to the miss. The province is the country's biggest market , so that's gotta hurt. He's been quite vocal with authorities about green lighting more legal locations, but it seems to be falling on deaf ears -- "Eh?"."Why it's not just happening right away, I do not know," Zekulin told BNN Bloomberg.He isn't expected to be "acting" much longer, as Canopy is reported to be zoning in on a permanent replacement for ousted co-founder and former CEO Bruce Linton.Now, as I was saying … let's take a closer look at CGC stock, and see why Cannabis 2.0 may not be enough to save the stock. * 7 Large-Cap Stocks to Give a Wide Berth Cannabis 2.0: Reality vs. Hype for CGC StockCanada legalized recreational marijuana sales last year. The "2.0" of legalization came just last month, with the regulatory green light for CBD- and THC-infused drinks, edibles and non-flower products.With Canopy's launch of Cannabis 2.0 products coming on schedule for early December, we are getting a clearer picture of the new product launches. A few weeks ago, Barron's took a look Canopy's upcoming products. The company is launching 13 cannabis-infused drinks, a line of cannabis-infused chocolate, as well as vape products.Is there demand for these products? Some 60% of cannabis users, and 80% of non-users want to try out infused beverages. With the drinks offering a low-THC buzz, they could be an alternative to alcoholic beverages like beer and wine.Cowen analyst Vivien Azer is bullish about Cannabis 2.0's impact on the industry. She projects these products could produce $2.3 billion CAD ($1.7 billion) in annualized sales by next year. But will this translate into revenue growth for Canopy? The company faces heavy competition in the beverage, edibles, and vapes space. Competitors like Hexo (NYSE:HEXO) have beverage launches of their own. Meanwhile, in its earnings report, the company said it used $404.7 million in cash, mostly for its operations, along with the construction of its manufacturing and beverage production facilities.While beverages are a big part of the Canopy Growth stock story, the company is pursuing other growth opportunities. Recently, Canopy announced a partnership deal with Drake. But this celebrity "cannabis wellness" venture may not be a slam dunk. Canopy's past celebrity partnerships have failed to pay off. These sorts of deals are good PR, but probably won't move the needle.Regulatory red tape remains a big headwind. A lack of retail locations makes it tough for companies like Canopy to unload swelling inventories. There's a lot at play for the future of CGC stock, and not all of it hinges on "Cannabis 2.0".With these risks and opportunities, is Canopy Growth stock priced for a contrarian bet? Let's look at valuation, and see if today's price presents a strong entry point. Canopy Growth Stock Richly Priced Relative to PeersUsing the enterprise value/sales (EV/Sales) ratio, CGC stock remains more expensive than most of its peers. Canopy trades at an EV/Sales (trailing 12 months) of 26.5x. Aurora Cannabis (NYSE:ACB) trades at trailing 12 month (TTM) EV/Sales ratio of 20.6x. Aphria (NYSE:APHA), Tilray (NASDAQ:TLRY), and Hexo all trade at lower TTM EV/Sales ratios than Canopy. Only Altria (NYSE:MO) backed Cronos Group (NASDAQ:CRON) trades at a higher valuation (TTM EV/Sales of 37.6).But Canopy's premium to ACB, APHA, TLRY, and HEXO could be justified. Like Cronos, Canopy is backed by a deep-pocketed partner. This provides the cash necessary to sustain operations as it scales to profitability. * 7 Great High-Yield Stocks With Payouts Over 5% As seen in my recent Cronos analysis, strategic partners can be a doubled-edged sword. With Cronos, Altria has incentive to drive the company's share price lower, allowing it to take it over on the cheap. The same situation could occur with Canopy Growth stock. If shares fall further, Constellation can step in and acquire a larger share of the company at lower prices.Constellation also has the opportunity to capture much of Canopy's potential upside. The beverage giant holds multiple tranches of warrants. The first tranche allows them to buy 88.5 million shares at $50.40 CAD a share. The second and third tranches allow them to buy 51.3 million additional shares at higher prices. With declines in the CGC stock price, Canopy extended the warrants' expiration date to November 2023 for the first tranche and November 2026 for the second and third.These warrants are priced at higher levels than Canopy's current trading price. But if the company rebounds, Constellation stands to reap much of the upside. Tread Carefully With CGC StockEven after falling from $52.74 per share down to below $20 a share, CGC stock is not cheap. High expectations for Cannabis 2.0 continue to be priced into shares. Investors today can make a bet that infused beverages and edibles pay off. But it's important to note the impact of Constellation's de-facto control of the company.So what's the play? Buy Canopy Stock if you're willing to stomach the risks. But other pot names selling at lower valuations may enable you to make that bet at a more reasonable price.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Stocks to Buy Under $10 * These 10 Stocks to Buy Make the Perfect 'Retirement' Portfolio * 5 Streaming Stocks to Buy for Huge Upside Over the Next Decade The post 'Cannabis 2.0' May Not Be Enough to Save Canopy Growth Stock appeared first on InvestorPlace.

  • Constellation Brands (STZ) Stock Sinks As Market Gains: What You Should Know

    Constellation Brands (STZ) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Constellation Brands (STZ) closed at $182.82, marking a -0.65% move from the previous day.

  • Is Canopy Growth Stock A Buy Right Now? Here's What Earnings, Charts Show
    Investor's Business Daily

    Is Canopy Growth Stock A Buy Right Now? Here's What Earnings, Charts Show

    Canopy Growth stock has been praised by many analysts. Here’s what chart analysis shows about buying this marijuana stock right now.

  • Canopy Growth's Drake Deal Eases Pullback as Q2 Earnings Near

    Canopy Growth's Drake Deal Eases Pullback as Q2 Earnings Near

    Canopy Growth (CGC) is set to report its second quarter results before the market opens on Thursday, November 14.

  • Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?

    Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?

    Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?


    Cronos Paid $300 Million for a Small CBD Company, and CEO’s Private-Equity Firm Stands to Collect $120 Million of It

    A fund founded by cannabis company’s CEO and a longtime board member owned 40% of a U.S. start-up that commanded a takeover price of up to 150 times its 2018 revenue

  • Financial Times

    Alcoholic fizzy waters claw sales from beer

    Take sparkling water, some cheap alcohol usually distilled from sugar, add some fruit flavouring, stick it in a brightly coloured can — and you have a new US drinks craze, “spiked seltzer”. The undisputed leader in this market is White Claw, a brand owned by private Canadian company Mark Anthony Brands, which had an unexpected boost at the start of the summer when a mocking YouTube video by comedian Trevor Wallace went viral.

  • Constellation Brands (STZ) Down 2% Since Last Earnings Report: Can It Rebound?

    Constellation Brands (STZ) Down 2% Since Last Earnings Report: Can It Rebound?

    Constellation Brands (STZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Holiday Spirits Are High Thanks to Canopy Growth’s Edibles

    Holiday Spirits Are High Thanks to Canopy Growth’s Edibles

    Canopy Growth (NYSE:CGC) released some excellent news on Oct. 29. If Canopy has anything to do with it, Christmas in Canada is going to be a whole lot more cheerful this year as cannabis-infused beverages and edibles make their way onto the menus of holiday house parties across the country. Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsI was having coffee recently with a friend of mine who works in the financial services industry. He's a fun guy, but still quite conservative by Canadian standards. He was telling me about how he was at a house party held by a wealthy acquaintance, and there on the dining room table were the options of beer, wine and pre-rolled joints. My friend couldn't believe it. Well, I sure could. And so could the big boys at Constellation Brands (NYSE:STZ) whose plan all along was to turn pot into a fourth revenue stream of so-called vice. However, while it's nice to offer pre-rolled joints at a party, the Canadian winters tend to get pretty cold. I'm not sure how many people are going to step outside to smoke a joint, especially when they can imbibe a cannabis-infused drink or eat chocolate edibles while staying warm and toasty inside.That's why Canopy is rolling out the perfect Yuletide treats Dec. 16. A Holiday SurpriseAt the Oct. 29 media event, reporters sampled the drinks that will go on sale shortly. As the Ottawa Citizen reported, "the samples were THC- and CBD-free but contained placebo substitutes meant to simulate the taste of the cannabis components." Canopy is being careful to keep the dosage relatively low so that consumers who've never tried cannabis can sample the products without having a bad experience. * 7 Stocks to Buy in November "This is meant to be a social product," CGC President Rade Kovacevic said. "To us, the mass market disruptive opportunity is to mimic beverage alcohol. That's the home run."I couldn't agree more. Come the holidays, I'm confident responsible hosts will provide them in limited quantities along with glasses of wine and beer.As I've said in the past, people my age (55 years old) are going to be far more interested in trying cannabis-infused drinks and edibles than they are smoking the dried flower. Many of my peers haven't smoked anything since they were in college. Interestingly, it only takes 14 employees at Canopy's 150,000 square-foot facilities to operate the beverage machines. That's less than 1% of the company's total workforce. Can you say "margins?" I knew you could. The Bottom Line on CGCAt the same time Canopy introduced its cannabis-infused drinks to the media, it also took the wraps off its new line of chocolate edibles. Those chocolates come through a partnership with Hummingbird Chocolate, an Ottawa-area chocolate maker.I'm partial to gummy bears and other candy. But I'd be more interested in trying a chocolate bar with 10 milligrams of THC. It takes an hour to feel the effects of this THC-infused chocolate, and as long as 10 hours for the effects to dissipate. On the other hand, the effects of smoking a joint are said to last as long as three hours. Research suggests that 80% of cannabis novices, defined as those who've never been high, are interested in trying cannabis beverages. Canopy Growth is wise to keep the dosage low until it has more empirical data that supports moving the THC levels above 10 milligrams. It's the responsible thing to do. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post Holiday Spirits Are High Thanks to Canopy Growth's Edibles appeared first on InvestorPlace.

  • Ambev Stock: 3 Significant Risks, 3 Reasons to Buy Anyway

    Ambev Stock: 3 Significant Risks, 3 Reasons to Buy Anyway

    Ambev (NYSE:ABEV) stock presents a conundrum for investors. The long-term drop in the equity and the dividend may point to a potential bargain. However, political and business headwinds in Brazil point to significant challenges. Deciding whether to buy Ambev stock, investors must weigh these benefits against both the risk and their risk tolerance.Source: Anton Garin / Most Americans have few reasons to know Ambev. The Sao Paulo-based brewery is a subsidiary of Interbrew International, a subsidiary of Anheuser-Busch InBev (NYSE:BUD). For most residents of the U.S., their familiarity with the company likely revolves around Labatt Blue, a familiar brand for those who visit Canada. Outside of the Canadian connection, Ambev operates in Latin America, primarily in its home market of Brazil. 3 Notable Risks of Ambev StockThis unfamiliarity with AmBev stock likely extends to its significant risks. For one, Ambev faces ongoing political turmoil in its home country. The company is currently contending with an antitrust complaint filed by competitors in Brazil. A group of 110 resellers and distributors alleges that ABEV has used its market position to push abusive commercial policies. If found guilty, AmBev could face a fine ranging from 0.1% to 20% of its revenue.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAlso, in 2015, Ambev was tied to the Operation Car Wash corruption scandal in Brazil. However, Ambev products faced a massive tax increase that year, despite charges that the firm made "inappropriate payments" to two former Brazilian presidents to prevent the hike. However, the increase went into effect despite the allegation. To Vince Martin's point, that would either point to the company's innocence or highlight how poorly the firm has mastered the art of bribery. * 7 Stocks to Buy in November Secondly, Vince Martin also makes another great point about the Brazil beer market itself. Brazil was the only one of the company's regions to decline in the first six months of the year. It also accounts for more than half of company profits. Many blame an emerging craft beer scene amid overall growth in the beer market. However, this may have begun to recover as the Brazil region saw modest revenue growth in the third quarter.Third, ABEV stock has experienced a downtrend since peaking at more than $9 per share in early 2013. After recovering to the $7.25 per share range in March 2018, the stock tanked, falling below $4 per share by the end of that year. It has spent about 18 months trading in a range and sells for around $4.30 per share as of the time of this writing.These risks increase the uncertainty surrounding ABEV stock. As of now, the company supports a forward price-earnings (PE) ratio of around 20.5. This might seem high for a company expected to post no profit growth this year and a 10.5% earnings increase in 2020. 3 Reasons to Buy ABEVHowever, ABEV stock offers some reward for the risks. First, the current dividend yield stands at 5.2%, assuming the expected 24 cent per share gets paid. The company pays a varied dividend on a non-consistent basis. It seems especially inconsistent as it has not yet made a payout in 2019.Secondly, the aforementioned 20.5 forward PE comes in much lower than the multiple for Constellation Brands (NYSE:STZ) and Diageo (NYSE:DEO). It also offers a higher dividend yield than Molson Coors (NYSE:TAP). While not the cheapest alcoholic beverage equity, it offers some unique benefits for investors willing to invest.Third, revenue also continues to hold up well. In the recent quarterly report, profits fell by 15.8% year-over-year due to higher income taxes. However, overall revenue increased by 5.9%. The only region to experience a decline was Canada, where they face more intense competition from craft beer. It also saw its highest growth in the Latin America south region, which prospers despite the economic turmoil in Argentina. Should I Buy ABEV Stock?Investors have good reasons to both avoid or take a chance on ABEV stock. The risks associated with the legal and business environment in Brazil may give investors second thoughts about buying at current levels. However, it has offered a generous, if volatile dividend. It also trades well compared to other alcoholic beverage peers. Growth in some regions also points to its resilience.As customers and Ambev adapt to the higher taxes, I expect profit growth to resume. Moreover, given the revenue growth, I expect the downward move in ABEV stock to break at some point. For those wanting a beverage stock and do not mind the risk, they should consider Ambev stock.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post Ambev Stock: 3 Significant Risks, 3 Reasons to Buy Anyway appeared first on InvestorPlace.

  • Boston Beer's hard seltzer Truly is about to pummel White Claw: analyst
    Yahoo Finance

    Boston Beer's hard seltzer Truly is about to pummel White Claw: analyst

    Step aside, White Claw, a reborn Truly is coming for your sales.


    Constellation Brands Lacks a Guiding Spirit

    Those looking for dividends from STZ should be cautious as consumers swap out beer for wine and distilled drinks, fires rage in California and tariffs hit European imports.


    Marijuana Stocks Have Gotten Crushed. Here’s What to Do With Them Now.

    Investors who hold stakes in companies like Canopy Growth—and are sitting on large paper losses—would do well to consider a “double-up strategy” using call options. We explain.


    Canopy Growth Pins Its Hopes on New Marijuana-Laced Drinks and Chocolates

    Canopy unveiled the menu of beverages and chocolates that it will start selling in December. Most of the 13 drinks had low-levels of THC—the cannabis ingredient that makes you high.

  • Would Constellation Brands, Inc. (NYSE:STZ) Be Valuable To Income Investors?
    Simply Wall St.

    Would Constellation Brands, Inc. (NYSE:STZ) Be Valuable To Income Investors?

    Could Constellation Brands, Inc. (NYSE:STZ) be an attractive dividend share to own for the long haul? Investors are...

  • Cannabis Sector: Piper Jaffray Favors Canopy and Cronos
    Market Realist

    Cannabis Sector: Piper Jaffray Favors Canopy and Cronos

    Piper Jaffray analyst Michael Lavery thinks that Canopy Growth and Cronos Group have good positions in the industry. They have strong cash positions.

  • 10 Hot Pot Stocks to Buy

    10 Hot Pot Stocks to Buy

    As we approach the one-year anniversary of the Agriculture Improvement Act of 2018, or the "farm bill" as it's better known, much has changed in the cannabis industry. With the bill de-scheduling industrial hemp and hemp-based derivatives, cannabis retail has flourished. Unfortunately, we can't quite say the same about pot stocks to buy.Call it a case of misplaced expectations. While the federal government green-lighting industrial hemp opened the doorway to products such as cannabidiol (CBD), business is still business. Essentially, investors weren't willing to cut much slack for pot stocks simply because of a groundbreaking law.As publicly traded cannabis firms produced disappointing earnings results, stakeholders increasingly lost their patience. With none of the major players stepping up, investors headed for the exits. Botanical specialists were no longer stocks to buy but stocks to dump while the going was good.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, the disappointment wasn't just limited to financial underperformance. A tragic and unfortunately-timed vaping crisis added to the woes. Several companies had invested deeply into cannabis-based vaping products, which are now under suspicion. * 7 Reasons to Buy Canopy Growth Stock Is the ride over in pot stocks? For the conservative investor, going green isn't the most appropriate strategy. Then again, this market subsegment has never advertised itself as a paragon of stability.For the risk-takers and contrarians, though, I believe pot stocks to buy are compelling, especially at these levels. With sentiment at rock bottom, this sector probably has nowhere to go but up. Further, the hysteria around cannabis products is misplaced, which I will demonstrate throughout this list.Therefore, if you've got the nerve, here are 10 pot stocks to buy that are on discount: Tilray (TLRY)Source: Jarretera / During the height of the marijuana craze, Tilray (NASDAQ:TLRY) was easily one of the most celebrated pot stocks to buy. At one point, TLRY stock touched $300 on an intra-day basis. Now, with shares just above $20 a pop, Tilray has absorbed one of the most devastating losses in recent memory.But if you're new to this market, I'd take another look at TLRY stock. For one thing, shares are very close to their initial public offering price of $17. In addition, hedge funds are starting to turn bullish on the embattled organization.They have reason to be. Mostly, Tilray specializes in medical marijuana solutions. As a result, they have more legal leeway to distribute their products. Keep in mind that Tilray was the first company to import medical marijuana into the U.S. Moreover, growing global support for medicinal cannabis bodes well longer-term for TLRY stock. Canopy Growth (CGC)Source: Shutterstock At the peak of its dominant market presence, analysts sang praises of Canopy Growth (NYSE:CGC). Here was an aggressively expanding company that provided the blueprint for success for other "weedpreneurs" to follow. Specifically, the bulls loved that Canopy inked a deal with beverage maker Constellation Brands (NYSE:STZ). With resources in hand, Canopy could drive their expansion, thereby lifting CGC stock.At least, that was the theory. But in reality, pot stocks - like any other investment class - had to follow the rules. This is where the underlying organization stumbled. Gradually, stakeholders lost confidence in Canopy's aggressive growth strategies. Furthermore, Canopy had gambled heavily on vaporizer products, months before the current lung illness epidemic. In a panic, CGC stock deflated badly.However, as I argued recently, the bears might themselves be too aggressive on CGC stock. Tellingly, prior to the vaping crisis, medical professionals acknowledged that vaping was safer than smoking. And people have been smoking pot for a long time. Therefore, vaping cannabis likely isn't the culprit of the vape-related epidemic. * 10 Stocks to Sell Before December's Meltdown Once the facts start coming out, Canopy Growth has a chance for a reprieve. Therefore, you can buy CGC stock before the bullish wave hits. Cronos Group (CRON)Source: Shutterstock Prior to the cannabis industry fallout, no one could get enough of pot stocks to buy. Amid this optimistic environment, big tobacco giant Altria Group (NYSE:MO) made a deal with Cronos Group (NASDAQ:CRON). Under the terms, Cronos received $1.8 billion to further their CBD ambitions. On the other end, Altria acquired a 45% stake in CRON stock.Many analysts have considered Cronos as one of the more reasonable pot stocks to buy. Unlike some rivals, management keeps tighter control of their financials. Additionally, Cronos has made smart acquisitive decisions with their funds, buying out CBD beauty brand Lord Jones. That move essentially gave CRON stock a foothold in the U.S. cannabis market.Unfortunately from a timing perspective, Cronos also invested heavily in vaping products. But as I mentioned about Canopy, the vaping crisis' culprit probably lies somewhere else. People have smoked all kinds of strange weed but we're all only hearing about the lung illness epidemic now.Based on the available evidence, I fully expect an exoneration of the vaporizer platform. As such, I believe the bearishness in CRON stock is overdone. Aurora Cannabis (ACB)In a bull market, many observers regard expansion -- even done aggressively - as a positive attribute. Among the major pot stocks to buy, Aurora Cannabis (NYSE:ACB) took growth expectations to heart. Perhaps throwing caution to the wind, management made multiple strategic acquisitions. Because of this mindset, ACB stock has the largest international footprint.However, in a bear market, the constant expansion comes at a serious fiscal cost. Many analysts, including our own Wayne Duggan, have explicitly warned about the company's cash burn problem. Since his story was published on July 22, ACB stock has dropped over 45%. As pot stocks continue to lose value, the volatility puts pressure on Aurora Cannabis' financials. * The 7 Best Penny Stocks to Buy Admittedly, Aurora is one of the riskiest pot stocks to buy. However, for the patient and iron-willed investor, ACB stock still has a viable pathway forward. That's because the global cannabis market is increasing, especially in traditionally conservative Asian countries. With the largest international footprint, Aurora is well positioned to advantage this trend, if it can just hold on. cbdMD (YCBD)Source: Shutterstock Easily one of the most exciting - albeit under-appreciated - names in the hemp and cannabis industry, cbdMD (NYSEAMERICAN:YCBD) is a name you will surely want to keep track of. A driving force behind cbdMD's cannabidiol products is that they don't contain THC, marijuana's psychoactive compound. And with the company's myriad offerings, YCBD stock will likely experience an uptick longer term.That's not all. If you take a look at their website, you'll find that cbdMD-branded products are considerably cheaper than their rival brands. For instance, their 300mg tinctures are priced $29.99, $10 below the listing price of their cheapest competitor, Hemp Fusion. With the high costs of CBD therapies, cbdMD gives you relief for your symptoms and your wallet.Plus, I love the fact that cbdMD is headquartered in Charlotte, North Carolina. One of the biggest benefits of legalization is that the cannabis industry provides employment opportunities for Americans. As economic uncertainty weighs on the markets, the political motivation for fully legalizing cannabis increases. Thus, I view this development as net positive for YCBD stock. Auxly Cannabis (CBWTF)Source: Shutterstock One of the reasons why pot stocks to buy haven't realized their full potential is the ever-present risk of reality not meeting hype. When Canada became the first G7 member to legalize recreational weed, it bolstered the bullish thesis for companies like Auxly Cannabis (OTCMKTS:CBWTF). But from mundane administrative issues to downright fraudulent actions, Canadian cannabis didn't live up to people's exaggerated expectations.With other harsh realities weighing on the sector, pot stocks largely crumbled. As you might expect, the volatility disproportionately impacted smaller shares like CBWTF stock. But it's in this backdrop of extreme negativity where we find "Cannabis 2.0." This is Canada's second go-around with weed as their government okays new product categories, including edibles, vapes, and topicals. * 10 Hot Stocks Staging Huge Reversals Will the second attempt prove favorable for CBWTF stock and the broader industry? While I don't want to get too ahead of myself, I can't help but feel a little excitement. After all, no one is really hyping Cannabis 2.0, especially with the vaping crisis on everyone's mind. This is setting up an alluring contrarian play for CBWTF stock. Origin House (ORHOF)Source: Shutterstock Formerly known as CannaRoyalty, Origin House (OTCMKTS:ORHOF) is a cannabis firm that made its name through streaming businesses. And while it still generates some revenue through its initial line of work, ORHOF has become a powerhouse in branding.The proof is in its utter domination of California. Unbeknownst to me prior to this write-up, the Golden State is the world's largest legal cannabis market. With a title like that, it's a wonder how anything gets done around here. Joking aside, Origin House boasts more than 450 California-based dispensaries and more than 50 popular brands.In other words, if you can make it in California, you can make it anywhere. This bodes very well for ORHOF stock. October's midterm elections proved that legal weed is gaining serious momentum. Inevitably, more recreational markets will open, allowing Origin House to expand its dominating presence.And that's just in the immediate sphere of influence. With medical cannabis making inroads in countries like Thailand, South Korea, and Japan, it opens possibilities. Theoretically, Origin House can replicate its branding prowess overseas, which would transform ORHOF stock. Marimed (MRMD)Source: Shutterstock If we graded pot stocks to buy on the sexiness scale, the producers would probably rank very highly. On the lower end of this spectrum would come in the administrators and logistics specialists. Yet no matter how exciting the cannabis industry is, it involves plenty of paperwork. And that's where Marimed (OTCMKTS:MRMD) and MRMD stock comes into play.In a crowded field, Marimed's biggest advantage is its highly demanded consultation services. Covering everything from licensing application support to facilities management, MRMD provides relevant and critical insights for budding entrepreneurs. Plus, in my opinion, Marimed levers one of the brightest and well-rounded leadership teams in the marijuana industry.Sure, it's the boring work of a groundbreaking industry. Still, it's got to get done, which drives the case for MRMD stock. * 10 Super Boring Stocks to Buy With Super Safe Returns Furthermore, MRMD stock has taken an absolute beating this year. But with the cannabis products increasing in adoption, now might be an ideal time to pick up shares on discount. Aleafia Health (ALEAF)Source: Shutterstock Broader and sector weakness has hurt virtually all marijuana stocks. However, the lesser-known names have experienced disproportionate pain. Unfortunately, this is something that Canadian cannabis firm Aleafia Health (OTCMKTS:ALEAF) knows all too well.But despite its severe market loss last year and its sharp decline in the year so far, ALEAF stock offers a speculative opportunity for risk-takers. For starters, the underlying company features the largest network of referral-only medical cannabis clinics in Canada. Furthermore, their patient base continues to increase as the industry gains social recognition and acceptance.Management has also invested heavily in cultivation facilities, targeting an annual growing capacity of 98,000 kilograms in 2019. Plus, with Cannabis 2.0 soon approaching, ALEAF stock has coincidentally slowed its descent. For the contrarian, this may present a great chance to buy into a compelling medical name. Diego Pellicer Worldwide (DPWW)Source: Shutterstock We've arrived at the end of our journey regarding marijuana stocks to buy in 2019. In keeping with my loose tradition, I like to throw in an extremely speculative name. And don't roll your eyes at me: you know you want to know!The following idea comes from an InvestorPlace reader named Anthony. He asked my opinion regarding Diego Pellicer Worldwide (OTCMKTS:DPWW). My answer to him is the same one I'm giving to you, which is that DPWW stock is extremely risky. Aside from its distressingly low trading volume and market capitalization, Diego Pellicer lacks financial strength to convincingly pull off its licensing and royalties business model.However, I'm intrigued with its premium branding business. Not that I would know, but Diego Pellicer specializes in high-class cannabis products. As companies like Origin House and Medmen have proven, cannabis users eschew quantity for quality. That could lead to a surprising turnaround for DPWW stock.Or you can lose every cent that you put in.As of this writing, Josh Enomoto is long MRMD and ALEAF. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons to Buy Canopy Growth Stock * 7 Restaurant Stocks to Leave on Your Plate * 4 Turnaround Plays to Buy Now The post 10 Hot Pot Stocks to Buy appeared first on InvestorPlace.

  • MoneyShow

    Constellation Brands- Wine, Beer Cannabis Drinks

    Constellation Brands (STZ) is a global manufacturer and marketer of wine, spirits, and beer with a wide range of brands, including Clos du Bois, Ruffino, Robert Mondavi, and SVEDKA vodka, notes John Staszak, an analyst with the independent research firm, Argus Research.

  • This Isn’t the Time to Buy Aurora Cannabis Stock

    This Isn’t the Time to Buy Aurora Cannabis Stock

    It's been a hard year for marijuana firms and their investors. The industry has been wracked with worries about health concerns, waning demand and regulatory tie-ups. Naturally, this has taken a toll on marijuana stock prices.Aurora Cannabis (NYSE:ACB) is a prime example of a pot stock that's been hammered over the past 12 months. ACB stock has fallen 67% from where it was a year ago and many are speculating that the industry hasn't bottomed yet.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Troubled IndustryOne of the big reasons the industry is struggling right now is the slow-moving legalization process in Canada. The government is struggling to get through a backlog of licensing requests. That means companies that want to operate within Canada's legal marijuana market sometimes have to wait over a year for a permit.Canada's so-called "Cannabis 2.0" is slated to begin on October 17. During that time, the nation will legalize vaping products, edibles and cannabis-infused beverages. On the surface, that looks like a near-term catalyst for ACB. But if the nation's last round of marijuana legalization is anything to go by, we might be waiting a long time to see the benefits. * The 7 Best Penny Stocks to Buy On top of that, the marijuana industry is bumping up against health concerns as well. Vaping has been linked to 33 deaths across the U.S. and thousands of "lung injury cases." What's worse is that the Centers for Disease Control and Prevention says the majority of those patients have a history of using products that contain THC, the psychoactive chemical found in marijuana. Issues Involving ACB StockOf course, the industry-wide issues with obtaining legal permits put all marijuana firms on a level playing field. However, the vaping concerns weigh heavily on ACB stock as the firm is making big bets on the future of that industry. Management has consistently pointed to vaping as an area of focus. So, if regulators clamp down to avoid health problems, it could have a negative impact on Aurora stock.There are many out there, though, who look at the vaping issues as little more than a blip on the radar. After all, cigarettes contribute heavily to a host of terminal illnesses, but that market is still open for business. That's true, but the vaping concerns aren't the only problems Aurora stock is facing.Aside from its vaping bets, investors purchasing ACB stock are taking on some risky financials as well.The firm is in need of cash to continue funding its growth plans and likely has nowhere to turn aside from capital markets. Next March, ACB will have 230 million CAD worth of convertible debt to pay off. If the firm's share price is still in the gutter, it's doubtful the lenders will be willing to take the stock-conversion option. That means Aurora will likely take on even more debt, a worrying prospect for shareholders. The Silver Lining for Aurora StockOverall, Aurora Cannabis stock looks like a pretty shaky investment. It's uncertain financials and decision to focus on vaping makes it a risky bet. However, the firm does have some things going for itself.Aurora's sales make it the largest player in Canada and margins have been improving as costs fall. Plus, the firm has finally outlined plans to enter the CBD market, which is poised to explode in the coming years.ACB has aligned itself with Ultimate Fighting Championship in order to test whether CBD is effective in treating pain. The results of the study will eventually help Aurora develop a line of topical CBD products aimed at athletes. Potential PartnershipAnother potential positive for ACB stock is the fact that the firm is making its way as a leader in the cannabis industry without the help (or control) of a larger partner from another industry. The firm's rivals Canopy Growth (NYSE:CGC) and Cronos Group (NASDAQ:CRON) have inked deals with Constellation Brands (NYSE:STZ) and Altria (NYSE:MO), respectively.Aurora, on the other hand, is still flying solo. If everything pans out, that would be an advantage for long-term ACB stockholders as both Cronos and Canopy are likely to be bought out by their partners before they realize their full potential.Not everyone believes going it alone is the best option. Larger partners mean deeper pockets and better funding, which is something Aurora Cannabis stock could use right now. Also, the cross-industry tie is likely to help as marijuana products bleed into other consumer product lines in the future.There's also some question as to why big names aren't aggressively pursuing Aurora. The firm brought on infamous strategic advisor Nelson Peltz in what many believed was an effort to secure a cross-industry partnership. The Bottom LineACB stock doesn't look like it's heading to zero, but it might get close. Moreover, 20 years from now the stock might be a winner, but for now I'd remain on the sidelines.If you've got time and you're a sucker for a large risk/reward payoff, Aurora stock could be a winner. However, for now I think your capital is better deployed until there's a clearer picture of the firm's future on the table.As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Penny Stocks to Buy * 7 Bank Stocks to Avoid Now at All Costs * The 10 Best Mutual Funds for Your 401k The post This Isna€™t the Time to Buy Aurora Cannabis Stock appeared first on InvestorPlace.

  • Exclusive: Florida Aquarium partners with Corona
    American City Business Journals

    Exclusive: Florida Aquarium partners with Corona

    The Florida Aquarium is diving head first into a new partnership agreement with the parent company of Corona. This will be the first time Corona will partner with an aquarium and its first partnership with a nonprofit in Tampa Bay. The Florida Aquarium’s outdoor cantina will be rebranded as Corona Cove and have a Corona-themed sculpture.

  • Benzinga

    Jim Cramer Shares His Thoughts On Canopy Growth, Procter & Gamble And More

    On CNBC's "Mad Money Lightning Round," Jim Cramer said Canopy Growth Corp (NYSE: CGC ) needs new CEO for the stock to trade higher. Constellation Brands (NYSE: STZ ) needs to buy more stock or ...

  • GlobeNewswire

    Modelo Partners with Anderson .Paak and iHeartMedia for Concerts Benefitting Refugees, Immigrants and Americans In Need

    Modelo, the beer brewed with The Fighting Spirit™, proudly announces it has teamed up with Anderson .Paak for the Modelo Fighting Chance Concert Series, an iHeartRadio production. Together, along with music fans, they are raising money for the International Rescue Committee (IRC) to help refugees, immigrants and Americans in need achieve their full potential. Modelo and iHeartMedia will give four lucky fans an opportunity to win VIP trips to New York to see Anderson .Paak in concert at Brooklyn Steel on November 17.

  • Will Coca-Cola's Product Expansion Stimulate Growth in the Remainder of Fiscal 2019?

    Will Coca-Cola's Product Expansion Stimulate Growth in the Remainder of Fiscal 2019?

    Coca-Cola (KO) is set to report their third quarter results before the opening bell on Friday, October 18th.

  • Benzinga

    Is Cannabis The Liquor Industry's Worst Nightmare?

    A new study by Syracuse University and the University of Georgia suggests cannabis legalization has a significant negative impact on online searches for alcohol and online alcohol advertising effectiveness. Surprisingly, the study found that tobacco interest is not negatively impacted by marijuana legalization. “The alcohol industry, by contrast, has valid reasons to be concerned about legal cannabis and may need creative strategies to avoid market decline if recreational cannabis legalization passes,” the researchers concluded.

  • Cannabis industry stumbles on financing concerns
    Yahoo Finance Video

    Cannabis industry stumbles on financing concerns

    Disappointing earnings from Canopy Growth, Tilray and Cronos have investors hesitant to invest in the cannabis industry. Yahoo Finance’s Heidi Chung, Brian Cheung and Sibile Marcellus discuss with Entourage Effect Capital CEO Matt Hawkins on YFi AM